| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442766 | European Journal of Cancer | 2014 | 9 Pages |
Abstract
Bevacizumab with 5-FU/streptozocin in the treatment of pancreatic NETs seems to be feasible with a PFS of 23.7Â months, which deserves further attention. No unexpected toxicity was observed.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Michel Ducreux, Laetitia Dahan, Denis Smith, Dermot O'Toole, Céline Lepère, Clarisse Dromain, Valérie Vilgrain, Eric Baudin, Catherine Lombard-Bohas, Jean-Yves Scoazec, Jean-François Seitz, Laurence Bitoun, Sébastien Koné, Emmanuel Mitry,